multicenter clinical

Related by string. * Multicenter : multicenter Phase II . multicenter study . multicenter randomized double . multicenter randomized . Multicenter Randomized Double / clinicals . CLINICAL . Clinicals . Clinical : Phase III clinical trials . Phase III clinical . placebo controlled clinical trials . Phase 2b clinical . Clinical Excellence NICE * multicenter clinical trials *

Related by context. All words. (Click for frequent words.) 76 prospective multicenter 75 multicentre randomized 75 placebo controlled clinical 74 multicenter randomized clinical 74 randomized controlled clinical 74 phase IIb clinical 74 randomized clinical 74 Phase IIIb clinical 73 randomized multicenter 73 phase IIa clinical 73 multicenter randomized 73 multicenter 73 multicenter prospective 72 placebo controlled Phase III 72 randomized Phase III 71 Phase III randomized 71 Phase IIIb study 71 Phase Ib clinical 71 randomized Phase IIb 70 Phase IIIb 70 Phase IIb clinical 70 prospective randomized 70 Phase 1b clinical 70 prospective randomized controlled 70 dose escalation clinical 70 multicenter Phase II 70 phase IIa 70 randomized controlled 70 Phase 2a clinical 70 multicenter randomized controlled 70 prospective randomized multicenter 70 Phase 2b study 70 phase IIIb 70 Phase 2b kidney transplant 69 double blinded randomized 69 clinical trial 69 Phase Ib II 69 multicenter study 69 placebo controlled randomized 69 label multicenter 69 prospective multicenter randomized 69 multicentre 69 RE LY 68 Phase IIb III 68 controlled multicenter 68 randomized blinded 68 dose escalation Phase 68 NO# [002] 68 EchoCRT 68 Phase III clinical 67 AIM HIGH 67 multicenter Phase 67 MIST II 67 multicenter randomized double 67 multicentre randomized controlled 67 BRIM3 67 multicenter randomized placebo controlled 67 Sorafenib HCC Assessment 67 Edwards SAPIEN valve 67 RE LY ® 67 dose escalation trial 67 Phase III VISTA 67 phase IIb 67 pivotal bioequivalence 67 PFO migraine 67 Phase IIb trial 67 COMFORT II 67 Phase 2b trial 67 Phase Ia 67 SPIRIT III 67 SPIRIT FIRST 67 multicentre randomized double 67 double blinded placebo 67 multicenter multinational 67 ADVANCE PD 67 ENESTnd 67 randomized multicentre 66 ENDEAVOR IV 66 placebo controlled Phase 66 BRIM2 66 TMC# C# 66 Phase IIb 66 Phase 2b clinical 66 ONTARGET 66 active comparator 66 randomized placebo controlled 66 phase IIb trial 66 CUSTOM III 66 Amrubicin 66 Eluting Coronary Stent System 66 randomized controlled multicenter 66 multicenter Phase III 66 TG MV 66 Phase #b/#a clinical 66 Phase 1b trial 66 REALITY Trial 66 ENDEAVOR III 66 Phase 2a trial 66 randomized controlled Phase 66 randomized multicenter trial 66 Phase III pivotal 66 ABSORB trial 66 prospective observational 66 Phase III psoriasis 65 OLYMPIA registry 65 Phase IIa clinical 65 Zilver PTX 65 everolimus eluting stent 65 ASTEROID 65 Carotid Revascularization Endarterectomy vs. 65 APEX PD 65 randomized Phase 65 BR.# 65 EDEMA3 65 CHAMPION PCI 65 Phase 1a clinical 65 trials RCTs 65 ToGA 65 phase Ib clinical 65 blinded randomized 65 multicenter phase 65 nonrandomized 65 prospective randomized placebo 65 confirmatory clinical 65 SPIRIT IV 65 Phase IIB 65 Phase #b/#a 65 Randomized controlled 64 prospective nonrandomized 64 AVADO 64 Phase Ib 64 TAXUS ATLAS 64 multicenter placebo controlled 64 Phase III randomized controlled 64 NeuroFlo 64 PERSEUS 64 EVEREST II 64 Randomized Evaluation 64 pharmacokinetic PK study 64 randomized multicenter Phase III 64 Prostate Lung Colorectal 64 oral ridaforolimus 64 Phase #/#a 64 metastatic HRPC 64 evaluating REVLIMID 64 blind multicenter 64 Phase 1b clinical trials 64 Phase IIa trial 64 NCCTG 64 assessing T DM1 64 RE MODEL 64 PRESEPT 64 confirmatory Phase III 64 blinded placebo controlled 64 TM Drug Eluting 64 Intervention Effectiveness 64 MEND CABG 64 neratinib 64 PARTNER Trial 64 randomized blinded placebo 64 XIENCE V Stent System 64 TAXUS TM 63 HCV SPRINT 63 pivotal Phase III 63 AIR CF1 63 XIENCE V Everolimus Eluting 63 AIR CF3 63 HCV RESPOND 2 63 CLARITY study 63 oral deforolimus 63 Endeavor drug eluting 63 crizotinib PF # 63 rALLy clinical trial 63 sunitinib malate 63 carotid endarterectomy CEA 63 SUCCEED trial 63 multicentre study 63 Stenting Trial CREST 63 multicenter clinical trials 63 Phase #/#a clinical 63 PRECISE 63 dose escalation study 63 Pivotal Trial 63 ZACTIMA 63 PROMUS Element Stent 63 AVERROES 63 Clinical Antipsychotic Trials 63 Pivotal Clinical Trial 63 Phase III 63 NSABP B 63 Investigational Device Exemption IDE 63 Sirolimus eluting Coronary Stent 63 ASCEND HF 63 CALGB 63 VITAL Trial 63 HORIZONS AMI trial 63 Ovarian Cancer Screening 63 Augment Injectable 63 phase 2a 63 CARE HF 63 Phase 2b 63 CALGB # [002] 63 thorough QT 63 phase IIb III 63 substudy 63 HPTN 63 randomized 63 pertuzumab 63 TAXUS IV 63 registrational Phase 63 randomized Phase 2b 63 Multicenter 63 eluting stent 63 Phase 2b clinical trials 62 viral kinetic 62 placebo controlled 62 blind randomized placebo 62 GEM OS1 62 Delcath Phase III 62 carotid artery stenting 62 phase IIb study 62 STRIDE PD 62 Ovarian PLCO Cancer 62 ADAGIO study 62 blind randomized 62 randomized double 62 Tryton Side Branch 62 YONDELIS 62 Phase Ib IIa clinical 62 ZoMaxx 62 Phase Ib study 62 Phase III Psoriasis 62 ABSORB clinical 62 CLARITY TIMI 62 bronchial thermoplasty 62 Cotavance 62 TAXUS Liberte 62 IIa trial 62 landmark ATHENA 62 fosbretabulin 62 INTERCEPT platelets 62 drug eluting stent DES 62 blinded randomized placebo controlled 62 masked placebo controlled 62 PROMUS R 62 lomitapide 62 Angiox R 62 PRECiSE 62 Screening Trial 62 oral rivaroxaban 62 designated HVTN 62 phase III ACCLAIM 62 prospective multicentre 62 everolimus eluting stents 62 ACUITY trial 62 pharmacokinetic PK 62 Phase Ib IIa 62 TAXUS Liberte Stent 62 randomized controlled clinical trials 62 subanalysis 62 EURIDIS 62 recurrent malignant glioma 62 BST CarGel R 62 Phase IIb kidney transplant 62 Phase III multicenter 62 randomized crossover 62 MADIT II 62 LUX Lung 62 ongoing Phase 1b 61 Endovascular Valve Edge 61 CUSTOM II 61 Phase III placebo controlled 61 Phase 1b dose escalation 61 IMPACT DCM 61 GetGoal Phase III 61 blinded randomized controlled 61 MADIT 61 NEVO 61 fidaxomicin Phase 3 61 NATRECOR R 61 Phase IIa trials 61 VADT 61 VESTASYNC 61 trastuzumab DM1 T DM1 61 recurrent glioma 61 dose dose escalation 61 ROCKET AF 61 phase Ib 61 IMPACT DCM clinical 61 NEVO ™ 61 TAXUS V 61 Dacogen injection 61 Phase IIa 61 multicenter trials 61 recurrent GBM 61 RSD# oral 61 Vectibix panitumumab 61 unblinding 61 EXPLORE Xa 61 pralatrexate injection 61 double blind placebo 61 galiximab 61 Xience Prime 61 CYPHER ® Sirolimus eluting 61 APTIVUS 61 zotarolimus eluting stent 61 paclitaxel eluting 61 trastuzumab emtansine T DM1 61 European Sepsis Trial 61 EFAPROXYN 61 AZILECT ® 61 TEMSO 61 BCIRG 61 HeFT 61 Phase IIb clinical trials 61 Raptiva ® 61 SWOG 61 dabigatran etexilate 61 ANCHOR trial 61 LUMINATE 61 PROTECT AF 61 bevacizumab Avastin 61 teriflunomide 61 multicentre prospective 61 EOquin TM 61 ritonavir boosted 61 PRIMO CABG 61 tanespimycin 61 randomized controlled trial 61 ExTRACT TIMI 61 Zenvia Phase III 61 CYPHER Stent 61 GAMMAGARD 61 ascending dose study 61 JAK inhibitor 61 SIR Spheres 61 sirolimus eluting stents 61 RIO Lipids 61 PFO closure 61 Phase III metastatic melanoma 61 Long Lesion 61 rALLy trial 61 ACRIN 61 AZILECT R 61 PERSEUS clinical program 61 CLL8 61 paclitaxel eluting stent 61 budesonide foam 61 CYPHER R Sirolimus eluting 61 registrational 61 RE COVER 61 Phase III Clinical Trial 60 riociguat 60 Xience V 60 Phase 2b randomized 60 APPRAISE 60 clinical pharmacology studies 60 relapsing multiple sclerosis 60 carotid artery stenting CAS 60 PRE SURGE 60 alvespimycin 60 Azedra 60 brivaracetam 60 Phase III confirmatory 60 NEVO RES 60 Acute Myocardial Infarction 60 label dose escalation 60 fully bioabsorbable 60 CRESTOR #mg 60 SYMMETRY trial 60 Sapien valve 60 ATACAND 60 ILLUMINATE 60 NEVO TM 60 ZYBRESTAT fosbretabulin 60 FOLOTYN ® 60 evaluating tivozanib 60 pain palliation 60 dose escalation phase 60 Levacor 60 forodesine 60 stent DES 60 HORIZONS AMI 60 sirolimus eluting 60 NCT# ClinicalTrials.gov 60 MGd 60 TELCYTA 60 CURRENT OASIS 7 60 MabCampath 60 BioSTAR R 60 Clinical Outcomes Utilizing Revascularization 60 Phase 1b 60 symptomatic BPH 60 LCP Tacro 60 IL# PE#QQR 60 Prospective Randomized 60 DAPT Study 60 novel oral anticoagulant 60 TAXUS Liberte stent 60 olaparib 60 LibiGel Phase III 60 Aryplase 60 SUTENT ® 60 BRAF inhibitor 60 Hepatocellular Carcinoma HCC 60 Prostate Cancer Prevention 60 GRAVITAS trial 60 CoAxia 60 MERLIN TIMI 60 label multicenter randomized 60 rFVIIa 60 clinical trials 60 blind randomized controlled 60 UPLYSO 60 arzoxifene 60 RESOLUTE 60 PROMUS TM 60 PROMUS Element Everolimus Eluting 60 relapsing remitting MS RRMS 60 Degarelix 60 Ixempra 60 recurrent glioblastoma multiforme 60 paclitaxel eluting stents 60 mg/m2 cohort 60 Phase III trials 60 Urocidin 60 Loramyc R 60 EINSTEIN DVT 60 Targretin capsules 60 Stent System 60 cediranib 60 dirucotide MBP# 60 axitinib 60 BETAS 60 Feasibility Trial 60 Acute Ischemic Stroke 60 TAXUS Element Stent System 60 Phase 2a 60 treatment naive genotype 60 DAPT 60 ATTRACT 60 Betaferon ® 60 Certican 60 rilonacept 60 Randomised 60 acyclovir Lauriad R 60 PRoFESS 60 TAXUS Element Paclitaxel Eluting 60 Coronary Stent System 60 doxorubicin docetaxel 60 DU #b 60 COSIRA trial 60 sorafenib Nexavar 60 relapsed refractory multiple myeloma 60 carotid stents 60 confirmatory Phase 3 60 Traficet EN 60 Initiated Phase 60 Endeavor stent 60 ENDEAVOR II 60 Endeavor Drug Eluting 60 Phase #b/#a trial 60 comparing XIENCE V 60 ACCORD Lipid 60 irbesartan 60 ThermoDox R 60 APEX AMI trial 60 OHR/AVR# 60 ascending dose 60 ACTIVE W 59 Multicenter Automatic Defibrillator Implantation 59 SEPET TM 59 carotid stent 59 ALTTO 59 Phase III HEAT 59 Corlux 59 TASKi3 59 RESOLUTE clinical 59 II Clinical Trial 59 Phase III ThermoDox 59 ENGAGE AF TIMI 59 HepaSphere 59 MADIT CRT 59 SUPERA stent 59 PEARL SC 59 Placebo controlled 59 Coronary Stent 59 EverFlex 59 placebo controlled multicenter 59 REPEL CV 59 Tarceva TM 59 IMPROVE IT 59 sorafenib tablets 59 Elocalcitol 59 enzastaurin 59 amrubicin 59 multicenter randomized Phase 59 tesmilifene 59 Allovectin 7 ® 59 DEEP AF 59 Cardiac Allograft Rejection 59 IIa clinical trial 59 Pivotal Study 59 Prostate AdenoCarcinoma Treatment 59 Drug Eluting Stent System 59 concurrent chemoradiation 59 LCP AtorFen 59 CHAMPION PLATFORM 59 drug eluting coronary stent 59 ixabepilone 59 Phase 1a 59 visilizumab 59 Clolar ® 59 reslizumab 59 elacytarabine 59 ARIXTRA 59 TAXUS VI 59 NSABP C 59 MAGE A3 ASCI 59 tolevamer 59 PREVAIL 59 noninferiority 59 PLCO 59 PrevOnco 59 EORTC 59 Aptivus 59 VESTAsync 59 ClosureFAST catheter 59 oral anticoagulant 59 BAY #-# 59 OvaRex ® MAb 59 Val HeFT 59 CYPHER ® Stent 59 GOUT 59 CAMMS# 59 DEB# 59 Ventavis 59 ACTEMRA TM 59 PHX# 59 Teysuno 59 IMA# 59 Sibutramine Cardiovascular Outcomes 59 Trobalt 59 nab paclitaxel 59 randomized clinical trials 59 MelaFind pivotal 59 Velcade bortezomib 59 BrachySil TM 59 pharmacodynamic effects 59 anti arrhythmic drug 59 iniparib 59 Trandolapril 59 ASPIRE HIGHER 59 Daclizumab 59 pegylated interferon alfa 2b 59 Combination REOLYSIN R 59 ThermoDox ® 59 patients undergoing percutaneous 59 Hexvix 59 OncoVex 59 TLK# 59 Onrigin 59 Ceplene/IL-2 59 sipuleucel T 59 NP2 Enkephalin 59 Aggressive Drug Evaluation 59 label multicenter Phase 59 CATIE AD 59 fenofibric acid 59 DASISION 59 candesartan cilexetil 59 ECASS 59 Taxus Liberte stent 59 Rilonacept 59 trial evaluating PRX# 59 KRN# 59 icatibant 59 pharmacokinetics PK 59 dose cohorts 59 mertansine 59 lorcaserin Phase 59 NSABP 59 EmbraceAC 59 SUTENT 59 clevidipine 59 AIR CF2 59 aflibercept 59 dirucotide 59 PROMACTA 59 interferon beta 1b 59 clinicaltrials 59 Ozarelix 59 REMEDIAL II 59 Pivotal Phase III 59 placebo controlled studies 59 Plenaxis TM 59 HeartNet 59 Myocet 59 MYTHOS trial 59 LEUKINE 59 Corus CAD 59 Phase III Trial 59 Resolute DES 59 OVATURE 59 Aflibercept 59 Phase III Pivotal 59 RE SURGE 59 AIR2 Trial 59 Endeavor Resolute DES 59 ORBIT II 59 induced macular edema 59 prospective multicenter study 59 phase III SIMPADICO 59 CIMZIA TM certolizumab pegol 59 CHARM Added 59 Randomized 59 Digital Mammographic Imaging 58 pitavastatin 58 midstage trials 58 AEGR 58 ELCAP 58 carotid stenting 58 Pertuzumab 58 Pirfenidone 58 Telcyta 58 mapatumumab 58 vemurafenib 58 ACCOMPLISH 58 fistulizing Crohn disease 58 FDA Investigational Device 58 urethral bulking agent 58 HoFH 58 MIVI III 58 PANVAC VF 58 evaluating Actimmune 58 ularitide 58 Phase III clinical trials 58 Multicenter Randomized 58 ONTARGET R 58 EDEMA4 58 Rheos System 58 ISEL 58 pivotal Phase 58 XIENCE V stent 58 unblind 58 recurrent ovarian cancer 58 Silodosin 58 AZOR 58 Alfimeprase 58 ARCOXIA 58 RG# [001] 58 SCD HeFT 58 PREVENT IV 58 varespladib 58 MIRCERA 58 eptifibatide 58 EMPHASIS HF trial 58 placebo controlled clinical trials 58 Trial NLST 58 Metricath Gemini 58 Heart Failure Trial 58 Endeavor DES 58 Edge STudy 58 TOLAMBA 58 Zemplar Capsules 58 Cloretazine ® 58 Macroplastique 58 Embolic Protection Device 58 Randomized Study 58 ponatinib 58 HGS# 58 orBec 58 metastatic hormone refractory 58 randomized #:# 58 Femara letrozole 58 CBLC# 58 retrospective observational study 58 DCVax ® Brain 58 CIMZIA TM 58 preclinical efficacy 58 sequential dose escalation 58 BARI 2D 58 NOXAFIL Oral Suspension 58 placebo controlled trials 58 transfemoral 58 bioabsorbable stent 58 tramiprosate Alzhemed TM 58 CardioFit 58 Rosuvastatin 58 rosuvastatin 58 Platelet Inhibition 58 EVIZON 58 fluvastatin 58 oral iron chelator 58 PROPEL trial 58 LEVADEX ™ 58 AeroLEF TM 58 Neurostep TM 58 AERAS-#/Crucell Ad# 58 Cimzia TM 58 Ranolazine 58 Nexavar sorafenib 58 Monitoring ABPM 58 Neo Bladder Augment 58 dosing cohorts 58 Intervention Effectiveness CATIE 58 PICSO ® 58 CoreValve System 58 elotuzumab 58 VNP#M 58 Ambrisentan 58 SilverHawk Plaque Excision System 58 Phase 2b monotherapy 58 sirolimus eluting stent 58 identifier NCT# 58 Proxinium TM 58 multidose 58 FOLPI 58 CAELYX 58 FIX HF 5 58 Anturol TM 58 Phase III Clinical Trials 58 vandetanib 58 IMPROVE HF 58 prospectively randomized 58 Quinamed 58 National Emphysema Treatment 58 Combo Stent 58 subcutaneous formulation 58 Endoscopic Ablation System 58 Icatibant 58 verteporfin 58 gadobutrol 58 ABSORB 58 Asentar 58 PROMUS 58 evaluating mipomersen 58 RCW breast cancer 58 INCB# [001] 58 SYNERGY Stent 58 XGEVA 58 RE LY trial 58 metastatic renal cell carcinoma 58 vidofludimus 58 investigational protease inhibitor 58 ISENTRESS 58 liposomal doxorubicin 58 angiotensin receptor blocker ARB 58 GTC recombinant human 58 lumiliximab 58 paclitaxel poliglumex 58 ADMIRE HF 58 Medtronic CoreValve 58 CYCLOSET 58 recurrent NSCLC 58 midstage studies 58 Augment Injectable Bone Graft 58 rosuvastatin #mg 58 TEMODAL 58 Acute Decompensated Heart Failure 58 GEM OS2 58 Myocardial Infarction Study 58 PROMUS Element 58 modified REGENESIS Phase IIb 58 MitraClip device 58 EXPAREL ™ 58 cangrelor 58 gefitinib Iressa 58 randomized placebo 58 OZURDEX ® 58 CB2 selective receptor agonist 58 GORE VIABAHN Endoprosthesis 58 refractory metastatic colorectal cancer 58 SANTE 58 International Verapamil SR 58 sunitinib Sutent 58 PreCISe 58 AQ4N 58 TAXUS Stent 58 Ereska 58 Phase IIb trials 58 ORMD 58 PROSTVAC ® 58 TRITON TIMI 58 Microplasmin 58 Octreolin 58 refractory CLL 57 Bronchitol 57 TORISEL 57 OncoVEX GM CSF 57 Dabigatran etexilate 57 StemEx R 57 TREDAPTIVE 57 dose melphalan 57 treatment naïve genotype 57 coronary stenting 57 IIa trials 57 plus prednisone 57 liver transplant recipients 57 MitraClip 57 label dose titration 57 ARIKACE 57 IIa clinical 57 ataluren 57 neoadjuvant 57 Tracleer R 57 Prospective Randomized Trial 57 Cloretazine 57 Randomized Phase 57 CONQUER OB 57 Blinatumomab 57 RezularTM 57 LEXIVA r 57 ASSERT trial 57 Dapagliflozin 57 TEC #OL 57 ZOLINZA 57 IN.PACT Falcon 57 myoblast therapy 57 multiple ascending dose 57 ImmuKnow assay 57 Diabetic Macular Edema 57 BrachySil ™ 57 Allovectin 7 57 Valtropin 57 atrasentan 57 retrospective cohort study 57 VICTOR E1 57 registrational trial 57 Epanova 57 Multi MERCI 57 PREDICTIVE 57 HuMax CD4 57 Phase III ADT 57 relapsed MM 57 acute PAO 57 lintuzumab 57 ticagrelor Brilinta 57 BioSTAR ® 57 metreleptin 57 ELONVA 57 Raptiva R 57 Spine Patient Outcomes 57 Temsirolimus 57 SABCS 57 dose cohort 57 Plicera 57 lorvotuzumab mertansine 57 gastrointestinal stromal tumors GIST 57 azilsartan medoxomil 57 tasocitinib 57 EQUIP OB 57 sunitinib 57 ORAL Sync 57 XIENCE V 57 pomalidomide 57 deforolimus 57 ROTATEQ 57 immunotherapeutic vaccine 57 Cordis Cypher 57 Phase IIA 57 Enzastaurin 57 Sym# 57 Augment Bone Graft 57 Ophena TM 57 NeuroStar TMS Therapy 57 Sipuleucel T 57 TASKi2 57 TAXUS Express Stent 57 ABCSG 57 acute coronary syndromes ACS 57 mechanical thrombectomy 57 Phase Ib clinical trials 57 WallFlex Biliary RX 57 Neulasta R 57 PSMA ADC 57 denufosol 57 ganetespib 57 Erbitux cetuximab 57 REVIVE Diabetes 57 DuraHeart 57 Mylotarg 57 TRANSFORMS 57 fostamatinib 57 Xience V stent 57 Dendreon Provenge 57 Transcatheter Cardiovascular Therapeutics TCT 57 Fibrin Pad 57 Ascendra transapical delivery 57 Archexin 57 TAXUS Liberte paclitaxel eluting 57 subgroup analyzes 57 ENDEAVOR IV clinical 57 RhuDex 57 Deforolimus 57 antiplatelet agent 57 Pemetrexed 57 RTOG 57 HOPE TOO 57 Vascular Wrap TM 57 TheraCIM 57 FAME Study 57 CLIRS trial 57 Tykerb lapatinib 57 POISE 57 Carotid 57 afamelanotide 57 lapatinib Tykerb 57 rNAPc2 57 Rubicon Filter 57 RRMS patients 57 PROMUS Stent 57 optimal dosing regimen 57 V Everolimus Eluting Coronary 57 Custom NX 57 CRLX# 57 tremelimumab 57 PREOS 57 Renal Cell Carcinoma RCC 57 CEQ# 57 Capesaris 57 docetaxel Taxotere ® 57 Olmesartan 57 ruxolitinib 57 Investigational Device Exemption 57 RG# ITMN 57 Zarnestra 57 NOX E# 57 temsirolimus 57 sNDA submission 57 Phase III randomized placebo 57 placebo controlled dose escalation 57 biliary tract cancer 57 Phase III registrational 57 MYDICAR 57 Thrombolysis 57 SCH # 57 Dupuytren Contracture 57 refractory angina 57 Vascular Wrap 57 PDX pralatrexate 57 prasugrel Effient 57 neoadjuvant treatment 57 dose escalation 57 randomized #:#:# 57 controlled multicenter Phase 57 Targretin 57 ACCEDE 57 TYKERB 57 blind placebo controlled 57 evaluating carfilzomib 57 TASQ 57 Nasdaq MAPP 57 MEND CABG II 57 unfractionated heparin UFH 57 ELACYT 57 number NCT# ClinicalTrials.gov 57 Tavocept 57 fidaxomicin Phase 57 Cetuximab Erbitux 57 Orazol 57 relapsed multiple myeloma 57 PROVENGE sipuleucel T 57 UKPDS 57 Resolute drug eluting 57 noninferior 57 ExCell study 57 TARGIT 57 bicifadine 57 PROPEL 57 TRISENOX 57 single ascending dose 57 Zelrix 57 Genasense ® 57 Evoltra 57 OncoVEX 57 drug eluting coronary stents 57 PROactive study 57 EASE Trial 57 iPrEx 57 Tanespimycin 57 Vascugel ® 57 Afatinib 57 Retisert TM 57 Stenting Trial 57 COPAXONE R 57 Zemiva 57 pancreatic neuroendocrine tumors 57 huC# DM4 57 observational cohort study 57 dose regimens 57 INCB# [002] 57 octreotide implant 57 Medidur TM FA 57 PROTECT II 57 Dabigatran 57 Androxal TM 57 investigational 57 intermittent dosing

Back to home page